Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 3/20 | 0.43 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.39 |
| ▸ | ITGB6 | P18564 | 1/20 | 0.39 |
| ▸ | ITGB8 | P26012 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 2/20 | 0.37 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.37 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 2/20 | 0.35 |
| ▸ | TEK | Q02763 | 2/20 | 0.35 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.35 |
| ▸ | MTOR | P42345 | 2/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | BRAF | P15056 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20792438 | 0.90 | ITGA5 (0.47) | RAF1ITGA5ITGB6ITGB8PPARG | |
| SCHEMBL30412293 | 0.90 | ITGA5 (0.47) | RAF1ITGA5ITGB6ITGB8PPARG | |
| SCHEMBL20764688 | 0.85 | ITGA5 (0.46) | RAF1ITGA5ITGB6ITGB8PPARG | |
| SCHEMBL30410775 | 0.85 | ITGA5 (0.46) | RAF1ITGA5ITGB6ITGB8PPARG | |
| SCHEMBL20743019 | 0.82 | SOS1 (0.45) | RAF1ITGA5ITGB6ITGB8HDAC1 | |
| SCHEMBL20764702 | 0.76 | ITGA5 (0.46) | RAF1ITGA5ITGB6ITGB8HDAC1 | |
| SCHEMBL20743289 | 0.75 | ITGA5 (0.45) | RAF1ITGA5ITGB6ITGB8KDR | |
| SCHEMBL20743024 | 0.75 | ITGA5 (0.45) | RAF1ITGA5ITGB6ITGB8MTOR | |
| SCHEMBL20764661 | 0.74 | ITGA5 (0.43) | RAF1ITGA5ITGB6ITGB8SLC6A9 | |
| SCHEMBL30411814 | 0.74 | ITGA5 (0.43) | RAF1ITGA5ITGB6ITGB8SLC6A9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111372928-B | Benzimidazole derivatives as potassium channel inhibitors | 阿塞西翁制药公司 | 2023-05-16 | — | — | CN | claimed |
| US-11168074-B2 | Potassium channel inhibitors | ACESION PHARMA APS (DK) | 2021-11-09 | — | — | US | claimed |
| EP-3672953-B1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS POTASSIUM CHANNEL INHIBITORS | ACESION PHARMA APS (DK) | 2021-07-28 | — | — | EP | claimed |
| US-20200255409-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | ACESION PHARMA APS (DK) | 2020-08-13 | — | — | US | claimed |
| EP-3672953-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS POTASSIUM CHANNEL INHIBITORS | Acesion Pharma ApS (DK) | 2020-07-01 | — | — | EP | claimed |
| WO-2019038315-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS POTASSIUM CHANNEL INHIBITORS | ACESION PHARMA APS (DK) | 2019-02-28 | — | — | WO | claimed |
| CN-111372928-B | Benzimidazole derivatives as potassium channel inhibitors | 阿塞西翁制药公司 | 2023-05-16 | — | — | CN | disclosed |
| US-11168074-B2 | Potassium channel inhibitors | ACESION PHARMA APS (DK) | 2021-11-09 | — | — | US | disclosed |
| US-11168074-B2 | Potassium channel inhibitors | ACESION PHARMA APS (DK) | 2021-11-09 | — | — | US | disclosed |
| EP-3672953-B1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS POTASSIUM CHANNEL INHIBITORS | ACESION PHARMA APS (DK) | 2021-07-28 | — | — | EP | disclosed |
| EP-3672953-B1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS POTASSIUM CHANNEL INHIBITORS | ACESION PHARMA APS (DK) | 2021-07-28 | — | — | EP | disclosed |
| US-20200255409-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | ACESION PHARMA APS (DK) | 2020-08-13 | — | — | US | disclosed |
| US-20200255409-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | ACESION PHARMA APS (DK) | 2020-08-13 | — | — | US | disclosed |
| CN-111372928-A | Benzimidazole derivatives as potassium channel inhibitors | 阿塞西翁制药公司 | 2020-07-03 | — | — | CN | disclosed |
| EP-3672953-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS POTASSIUM CHANNEL INHIBITORS | Acesion Pharma ApS (DK) | 2020-07-01 | — | — | EP | disclosed |
| WO-2019038315-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS POTASSIUM CHANNEL INHIBITORS | ACESION PHARMA APS (DK) | 2019-02-28 | — | — | WO | disclosed |
| WO-2019038315-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS POTASSIUM CHANNEL INHIBITORS | ACESION PHARMA APS (DK) | 2019-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200255409-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | KCNN1, KCNN2, KCNJ2 | RAF1 641/4885ITGA5 3438/4885ITGB6 3377/4885 |
| US-11168074-B2 | Potassium channel inhibitors | KCNN2, KCNJ2, KCNN1 | RAF1 744/4885ITGA5 2901/4885ITGB6 2859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.